Falken Industries Ltd, OTC : FLKI announces the broadest-based, fastest acting, most effective and safest anti-microbial known.

FLKI’s proprietary platform technology has proven effective in surface, water, and airborne applications and recently in military and civil defense.

Falken Industries Ltd is as little known by the public for its ambitious work as a specialty chemical and wipe technology based life science developments as it is well known for its conceptions in auto care products, professional body and detailing, industrial cleaning and disinfection the most notable of which are the Clean Plus® branded and globally distributed collections.

Falken now is well advanced with its plan to commercialize a product concept consisting of combinational chemistry-based technology including advanced development of its world leading position for wet wipe conceptions. Falken’s present technology can neutralize harmful environmental contaminants, toxins, and dangerous microorganisms. The obvious of which are spores, mold, fungi, bacteria, and viruses.  To accommodate this ambitious project the company has substantially increased its R&D and expanded its research facilities as was announced some time back.

The Company’s formulations include eco-friendly and natural and common ingredients. FLKI researchers using a mixture of commonly used compounds utilizing FLKI’s well known specialization have succeeded in creating products that significantly enhance disinfecting and cleaning results. FLKI’s proprietary platform technology has proven effective in surface, water, and airborne applications and recently for military and civil defense.

Product conceptions based on the company’s proprietary SN10® platform, disinfect, decontaminate, and sterilize. Falken’s development team’s mission is to bring to market the broadest-based, fastest acting, most effective and safest anti-microbial known. The company believes this class of products has important applications for healthcare facilities, consumer and household use, industrial applications, as well as the proven utilization for military and Homeland Security.

Falken’s product conceptions, irreversibly bind chemical contaminants and toxin molecules rendering them harmless. Applications for this product include industrial pollution, environmental contaminants, and protection against chemical weapons of mass destruction as was recently announced.

Today, Falken announced that lab test results demonstrated that SN10® consumer grade antimicrobial totally eradicated the H1N1 Swine Flu Virus in 15 seconds. This is a significantly milder and diluted variation of its institutional grade formulations. The testing shows that SN10® equaled the performance of the company’s hospital grade formulation, and that the formulation is extremely effective against the Swine Flu.

Falken Communication Officer Manuel Garcia stated, “Falken’s improved SN10® consumer grade antimicrobial immediately available throughout Europe and 27 other countries, is an important addition to the Company’s growing list of formulations which will be presented for the US markets to the EPA, for regulatory approval.”

About Falken Industries Ltd
Falken Industries Ltd OTC : FLKI is a diversified industrial conglomerate that operates in Chemicals, Wet Wipe and Biodegradable Technology. Falken Industries Ltd is the concept behind more than 160 products distributed through a network of global platforms and the recipient of trade awards for innovations, biodegradability and environmental and health quality standards. 





SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" made pursuant to the safe harbor provisions of the 1995 Private Securities Litigation Reform Act. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." Such statements are subject to risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or perform as intended, that we may be unable to obtain necessary financing to continue operations and development, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements